title: [Possibilities of medical correction of moderate cognitive impairment].
abstract: Thirty-four outpatients with moderate cognitive impairment were treated with one of standard extracts of Ginkgo Biloba - EGb761 (memoplant). Memoplant was used in high dosages (240 mg daily) twice a day during three months. Patients were assessed using the Montreal Cognitive Assessment (MoCA), the hospital depression scale and QoL questionnaire EQ5d as well as standard neurological and somatic examination. A statistical analysis of data revealed a significant improvement in most measures, mostly in attention, memory, orientation and visual-spatial/ executive functions as well as in anxiety and depression. The drug is well-tolerated and is recommended for practical use.
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
authors.forename: A V
authors.initials: AV
authors.lastname: Lebedeva
authors.forename: I A
authors.initials: IA
authors.lastname: Shchukin
authors.forename: M A
authors.initials: MA
authors.lastname: Soldatov
authors.forename: A M
authors.initials: AM
authors.lastname: Ismailov
authors.forename: R K
authors.initials: RK
authors.lastname: Shikhkerimov
authors.forename: O V
authors.initials: OV
authors.lastname: Otcheskaia
authors.forename: A A
authors.initials: AA
authors.lastname: Khozova
mesh_terms: D000368:Aged; D003071:Cognition / Q000187:drug effects / Q000502:physiology*; D060825:Cognitive Dysfunction / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D020441:Ginkgo biloba; D006801:Humans; D008297:Male; D008568:Memory; D008875:Middle Aged; D009483:Neuropsychological Tests; D010045:Outpatients; D008517:Phytotherapy / Q000379:methods*; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D000096983:Ginkgo Extract
chemical_list: D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract